CompletedPhase 2NCT03407651
Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Catalyst Biosciences
- Principal Investigator
- Howard Levy, MD, PhD, MMMCatalyst Biosciences
- Intervention
- Coagulation Factor VIIa variant(biological)
- Enrollment
- 11 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2017 – 2019
Study locations (9)
- Hematology Center after Prof. R. Yeolyan, Yerevan, Armenia
- JSC "K.Eristavi National Center of Experimental and Clinical Surgery", Tbilisi, Georgia
- LTD M.Zodelava Hematology Centre, Tbilisi, Georgia
- LTD Medinvest - Institute of Hematology and Transfusiology, Tbilisi, Georgia
- Gabinet Lekarski, Bartosz Korczowski, Rzeszów, Poland
- Regional Clinical Hospital, Kemerovo, Russia
- FGU Kirov Scientific Research, Kirov, Russia
- Center for Hemophilia Treatment, Saint Petersburg, Russia
- Haemophilia Comprehensive Care Centre, Johannesburg, South Africa
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03407651 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.